MediQuest Therapeutics said Friday that the U.S. Food and Drug Administration turned down its application to launch a treatment to treat Raynaud's Disease.
MediQuest Therapeutics said Friday that the U.S. Food and Drug Administration turned down its application to launch a treatment to treat Raynaud’s Disease.
The Bothell-based company said it received an FDA letter saying that the treatment “could not be approved in its present form.” The agency identified issues that need to be addressed by the company, but such issues were not disclosed. The company said it will provide an update “when appropriate.” The news was first reported by the website Xconomy.
MediQuest had requested expedited approval for what would have been the first product marketed for Raynaud’s disease, an ailment that constricts blood flow to the extremities.
Mediquest has 25 employees and has raised some $33 million from investors since 2006.
Most Read Business Stories
- Amazon sued by Black cloud-computing manager over alleged racial discrimination and sexual harassment
- The penthouse atop Smith Tower is on the rental market for the first time
- Costco, Whole Foods rise in Greenpeace rankings of grocery chains' plastic use
- Screening to detect prior coronavirus infections launched by Adaptive Biotech, with Microsoft's help
- Downtowns will be back, but Seattle has choices to make
Ángel González: 206-515-5644 or firstname.lastname@example.org